New drug combo tested to shrink lung tumors before surgery
NCT ID NCT07256509
Summary
This study is testing whether adding an investigational drug called SYS6010 to the standard drug osimertinib is more effective at shrinking tumors before surgery for patients with a specific type of lung cancer (EGFR-positive, non-squamous NSCLC). It will enroll 120 adults with stage II-IIIB cancer who have not had prior treatment. The main goal is to see if the combination leads to more patients having very little or no cancer left in the tumor removed during surgery.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.